Case report demonstrates spontaneous regression of eruptive melanocytic naevi after stopping encorafenib in metastatic colorectal cancer, highlighting paradoxical MAPK activation.
We report the first case of spontaneous regression of eruptive melanocytic naevi (EMN) following cessation of encorafenib, a BRAF inhibitor, in a patient treated for BRAFV600E-mutated metastatic colorectal cancer. The patient developed approximately 40 widespread naevi within two months of starting treatment, which showed near-complete involution within 12 months of drug withdrawal, confirmed on serial full-body photographic mapping and histopathology. This case supports the proposed mechanism of paradoxical MAPK pathway activation as the driver of BRAFi-associated EMN, and highlights the importance of dermatological surveillance in patients receiving BRAF-targeted therapies.
No takes yet. Share an insight, caveat, or question.
Selvendran et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: